ClinicalTrials.gg
CompletedNCT06555640Updated Jan 13, 2026

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

A Phase 2 interventional study of DR10624 Injection and Placebo in Severe Hypertriglyceridemia, sponsored by Zhejiang Doer Biologics Co., Ltd.. Completed at 35 sites in China. Open to participants aged 17 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
17 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Hypertriglyceridemia with a site in China — 14 open to participants now, 19 under way, 5 of them phase 3. Hypertriglyceridemia · China.

Enrollment
16th of 25
79 · median 119
Started
2024
with 1 other
Phase 2
5 of 26
2 open now
Registered
8th of 26
by date
Lead sponsor
4 of 26
Zhejiang Doer Biologics Co., Ltd.

Among the 26 studies in Hypertriglyceridemia with a site in China, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 8th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

14 of the 26 studies in Hypertriglyceridemia with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 17 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypertriglyceridemia with a site in China, or all of them as a file.
02

Study summary

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).

Read the detailed description

The subjects will be randomly assigned to experimental groups and placebo-controlled groups. Each participant will be enrolled in only one cohort.

03

Conditions studied

  • Severe Hypertriglyceridemia

Browse trials for

04

Who can participate

Ages eligible
17 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Subjects or their legally acceptable representatives must be able to provide written , understand the procedures and methods of the study, and agree to comply with all protocol requirements.

    2.Male or female, age of 18 to 75 years (inclusive) at screening.

    3.Subjects must have a of >19 kg/m2 and BMI of ≤45.0 kg/m2 , and body weight ≥50 Kg at screening.

    4.During screening or within 1 week prior to screening, the TG levels should meet the following criteria: 4.80 mmol/L (425 mg/dL) ≤ fasting TG \< 22.60 mmol/L (2000 mg/dL).

    5.The average fasting TG level of Visit 2 and Visit 3 values must meet: 5.65 mmol/L (500 mg/dL) ≤fasting TG \<22.60 mmol/L(2000 mg/dL); or the average fasting TG level of Visit 3 and Visit 3.1 values must meet the same criteria.

    6.Subjects will able to accept rencommendation on therapeutic lifestyle modificationa and maintain a stable lifestyle for the duration of the study.

    7.Subjects who are receiving statins, cholesterol-absorption inhibitor (CAI), fibrates, niacin ≥500 mg/day, or prescription omega-3 fish oil must have achieved a stable dose for at least 4 weeks before screening.

    8.Subjects diagnosed with type 2 diabetes(T2DM) must have a glycosylated level at screening of\<9.5%(80 mmol/mol)and treated with lifestyle modification or a stable doses of antidiabetic medications for at least 8 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • 1.Subjects with known familial hyperchylomicronemia (Fredrickson type 1) ,apo c-II deficiency,or familial β-lipoprotein dyslipidemia (Fredrickson type 3); or subjects with a high suspicion of having this three conditions.

    2.Subjects who have lost ≥5% of body weight within 3 months prior to screening, or who lose ≥5% of body weight during screening, or who plan to lose body weight during the study.

    3.Subjects with type 1 diabetes, or nephrotic syndrome.

    4.Subjects with cirrhosis, alcoholic liver disease, liver failure, liver cancer, or hepatitis.

    5.Subjects type 2 diabetes with a duration of less than 12 weeks or with severe complications.

    6.Uncontrolled hypertension at screening, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg under medication conditions.

    7.Subjects with an active or untreated or who have been in remission from a malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for \<5 years prior to screening.

    8.Subjects with a family or personal history of medullary thyroid carcinoma (MTC),multiple endocrine neoplasia syndrome type 2 (MEN2),severe active or unstable major depressive disorder (MDD), or other serious mental disorders (such as schizophrenia, bipolar disorder, or other severe mood or anxiety disorders) or suicidal.

    9.Subjects with a known clinically significant gastric emptying abnormality (e.g. severe diabetic gastroparesis), and who have undergone or plan to undergo gastric bypass surgery or gastric banding surgery during the study, or those who chronically take drugs that directly affect GI motility.

    10. Functional Classification III or IV CHF.

    11.In the opinion of the investigator, the subjects are likely to require concurrent treatment with systemic during the trial due to comorbidities.

    12.Subjects with a history of acute pancreatitis within 1 year prior to screening, or a history of chronic pancreatitis, or symptomatic of gallbladder disease (e.g. choledocholithiasis, gallbladder multiple stones, unless treated with cholecystectomy).

    13.Subjects with any of the following cardiovascular (CV) conditions within 6 months prior to screening: acute myocardial infarction, cerebral hemorrhage or cerebral infarction (except lacunar infarction), or hospitalization due to CHF, unstable angina pectoris or , or cardiac surgery such as percutaneous coronary intervention and coronary artery bypass grafting,or subjects who have been treated with GLP-1R agonists, or have participated in a clinical study involving GLP-1R and received the study drug within 6 months prior to screening.

    14.Subjects who have undergone large-sized surgery,have been treated with GCGR or multiple target point and agonists containing FGF-21R targets;have been treated with SiRNA type and monoclonal antibody type of PCSK9 inhibitors;or who have participated in a clinical study related to above all the types of drug within 3 months prior to screening.

    15.Subjects with severe trauma, severe infection who have not recoveredwithin 4 weeks prior to screening,who have been treated with DPP-4 inhibitors, or have participated in a clinical study related to DPP-4 inhibitors and received the study product;who have undergone lipid apheresis or plasma exchange treatment within the last 4 weeks or plan to undergo apheresis or plasma exchange during the study period.

    16.Subjects with hyperthyroidism or hypothyroidism who have the stable dose of therapeutic drugs less than 3 months prior to screening.

    17.Subjects with Cushing's syndrome or who have continuously or cumulatively used systemic glucocorticoids for more than 14 days within 6 months before screening, Inhaled or topical corticosteroids are permitted.

    18.Subjects who do not agree to discontinue medications, supplements, or nutraceuticals that have lipid-altering effects other than those specified in the protocol.

    19.Subjects who are taking insulin or second-generation antipsychotics and cannot stop taking them.

    20.Serum calcitonin ≥20 ng/L (pg/mL) in subjects with ≥60 mL/min/1.73 m2 , or serum calcitonin ≥35 ng/L (pg/mL) in subjects with eGFR \<60 mL/min/1.73 m2.

    21.>3.0 × value (ULN) and/or aspartate aminotransferase>3.0 × ULN and/or total >1.5 × ULN.

    22.Glomerular filtration rate eGFR \< 45 mL/min/1.73 m2

    23.TSH > upper normal limit or \< lower normal limit.

    24.Serum amylase or lipase > 2.0 × ULN.

    25. \< 110 g/L (males) or \< 100 g/L (females).

    26.Test positive for (HIV), virus (HBV), or virus (HCV), HBV and HCV determined by antibodies first and, if positive, by DNA/ribonucleic acid (RNA).

    27.Clinically significant 12-lead (ECG) abnormalities at the time of screening.

    28.History of drug abuse or excessive alcohol consumption within 3 months prior to screening.

    29.Presence of potential allergies to the study drug, its ingredients, or drugs of the same class.

    30.Pregnant or lactating women;as well as men and women of who are unwilling to prevent pregnancy throughout the study and within the specified time after the study.

    31.Blood donation and/or blood loss ≥400 mL, or bone marrow donation within 3 months prior to screening.

    32.Subjects in which the investigator deems to that there are any other factors may affect the efficacy or safety evaluation of this study(including medical, psychological, social, or geographical considerations) .

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Cohort 1: DR10624 injection

    DR10624 injection administered weekly (QW)

    Drug: DR10624 Injection

  • Placebo comparator
    Cohort 1: Placebo

    Placebo administered weekly (QW)

    Drug: Placebo

  • Experimental
    Cohort 2: DR10624 injection

    DR10624 injection administered weekly (QW)

    Drug: DR10624 Injection

  • Placebo comparator
    Cohort 2: Placebo

    Placebo administered weekly (QW)

    Drug: Placebo

  • Experimental
    Cohort 3: DR10624 injection

    DR10624 injection administered weekly (QW)

    Drug: DR10624 Injection

  • Placebo comparator
    Cohort 3: Placebo

    Placebo administered weekly (QW)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change of fasting TG

    The percentage change of fasting TG in all the participants from baseline to Week 12

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Change of lipid profile and lipoprotein profile

    The percentage change of fasting total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-high density lipoprotein cholesterol (non-HDL-C), very low density lipoprotein cholesterol (VLDL-C), free fatty acid (FFA), triglyceride rich lipoprotein cholesterol (TRL-C), lipoprotein (a) \[Lp(a)\], apolipoprotein C3 (Apo C3), apolipoprotein B (Apo B), apolipoprotein B48 (Apo B48), apolipoprotein B100 (Apo B100), apolipoprotein A1 (Apo A1) and apolipoprotein A5 (Apo A5)

    Time frame: From baseline to Week 12

  2. Number of participants whose fasting TG lowered by at least 50%

    The number of participants whose fasting TG decreased by at least 50% from baseline

    Time frame: From baseline to Week 12

  3. Change of glycosylated hemoglobin (HbA1C)

    The change of glycosylated hemoglobin (HbA1C) in all participants

    Time frame: From baseline to Week 12

  4. Change of liver fat content

    Measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF)

    Time frame: From baseline to week 12

  5. Change of liver stiffness measurements (LSM)

    The change of liver stiffness in subjects with baseline hepatic fat fraction of at least 8% measured by FibroScan

    Time frame: From baseline to week 12

  6. Change of controlled decay index (CAP)

    The change of CAP in subjects with baseline hepatic fat fraction of at least 8% measured by MRI-PDFF

    Time frame: From baseline to week 12

  7. Incidence and severity of adverse events

    The number of participants with treatment-related adverse events as assessed by CTCAE V5.0, such outcomes are included but not limited to hypoglycemia events, injection site reactions, 12-lead Electrocardiogram (ECG) QTc intervals and vital signs (blood pressure, heart rate, respiratory rate and body temperature), physical examinations and safety laboratory tests, etc.

    Time frame: through study completion, up to 17 weeks

  8. Anti-drug antibody(ADA)

    Anti-drug antibody(ADA)

    Time frame: through study completion, up to 17 weeks

  9. Pharmacokinetic Ctrough blood concentration of DR10624

    Pharmacokinetic Ctrough blood concentration of DR10624

    Time frame: through study completion, up to 17 weeks

07

Study locations

35 sites
  • Baoding No.1 Central Hospital
    Baoding, China
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, China
  • Peking University First Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, China
  • The First Hospital of Jilin University
    Changchun, China
  • The Second Hospital of Jilin University
    Changchun, China
  • Second Xiangya Hospital of Central South University
    Changsha, China
  • Chifeng Municipal Hospital
    Chifeng, China
  • Daqing People's Hospital
    Daqing, China
  • The Affiliated Hospital of Hangzhou Normal University
    Hangzhou, China
  • The Fourth Hospital of Harbin Medical University
    Harbin, China
  • The First Affiliated Hospital of South China University
    Hengyang, China
  • Inner Mongolia People's Hospital.
    Hohhot, China
  • Huzhou Central Hospital
    Huzhou, China
  • Lishui Municipal Central Hospital
    Lishui, China
  • Luoyang Third Peoples Hospital
    Luoyang, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, China
  • Meihekou Central Hospital
    Meihekou, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, China
  • The Third Hospital of Nanchang
    Nanchang, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, China
  • The Affiliated Hospital of Nantong University
    Nantong, China
  • Nanyang Central Hospital
    Nanyang, China
  • Panjin Liaoyou Baoshihua Hospital
    Panjin, China
  • Pingxiang People's Hospital
    Pingxiang, China
  • The People's Hospital of Liaoning Province
    Shenyang, China
  • Shaanxi Provincial People's Hospital
    Xi'an, China
  • The Third Affiliated Hospital of Xinjiang Medical University
    Xinxiang, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
  • Yancheng First People's Hospital
    Yancheng, China
  • Yixing People's Hospital
    Yixing, China
  • Yiyang Central Hospital
    Yiyang, China
  • Yueyang Central Hospital
    Yueyang, China
  • Yuncheng Central Hospital
    Yuncheng, China
  • Zibo Municipal Hospital
    Zibo, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2025, 10 months.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 15, 2024
StartActual
Aug 1, 2024
Primary completionActual
Jun 30, 2025
CompletionActual
Aug 29, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06555640
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Aug 1, 2024
Primary completion
Jun 30, 2025
Completion
Aug 29, 2025
Last update
Jan 13, 2026

Study contacts

Jianping Li, M.D.
study chair · Peking University First Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DR10624

Start the discussion